Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
羅氏基因泰克Vabysmo新的長期數據顯示，視網膜持續乾燥，視網膜靜脈閉塞（RVO）視力得到改善
– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –
Vabysmo能夠持續有效地乾燥視網膜液體，通常伴有變形或模糊視覺。
– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –
接受Vabysmo治療的人中，高達60％的人能夠將治療間隔延長至三到四個月。
– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024 –
兩項全球Phase III RVO研究的詳細結果將在2024年的“血管生成、滲出和退化”會議上介紹。
– Vabysmo is approved in the U.S. for RVO, and in more than 90 countries around the world for people living with wet AMD and DME –
Vabysmo已在美國獲得RVO的批准，並在全球90多個國家爲患有溼性黃斑變性和DME的人提供服務。